Clinical utility of ramucirumab in non-small-cell lung cancer

Source: Biologics: Targets and Therapy - Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research

Related Links:

Publication date: Available online 20 August 2019Source: Pharmacological ResearchAuthor(s): Hong-Yuan Lu, Yu-Xin Zu, Xiao-Wen Jiang, Xiao-Tong Sun, Tian-Yi Liu, Ruo-Lan Li, Qiong Wu, Ying-Shi Zhang, Qing-Chun ZhaoAbstractAcquired drug-resistant non-small cell lung cancer (NSCLC) has strong proliferation ability and is prone to epithelial-mesenchymal transition (EMT) and subsequent metastasis. Notch pathway mediates cell survival and EMT and is involved in the induction of multidrug resistance (MDR). ZLDI-8 is an inhibitor of Notch activating/cleaving enzyme ADAM-17 we found before. However, the effects of ZLDI-8 on resista...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
Background: Poziotinib is a potent, orally available, EGFR and HER2 exon 20-selective tyrosine kinase inhibitor used to treat nonsmall cell lung cancer (NSCLC). During a Phase 2 clinical trial of poziotinib, a high incidence of cutaneous reactions were reported in treated patients. Up to 55% of patients received a dose reduction in response to adverse events, most commonly from skin reaction and diarrhea.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
A combination of AstraZeneca's lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations, the drugmaker said on Wednesday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Publication date: September 2019Source: The Annals of Thoracic Surgery, Volume 108, Issue 3Author(s): Donglai Chen, Yiming Mao, Junmiao Wen, Yunlang She, Erjia Zhu, Feng Zhu, Yongsheng Zhang, Min Fan, Chang Chen, Yongbing ChenBackgroundA series of studies have assessed the clinicopathological features and prognostic impact of spread through air spaces (STAS) in non-small cell lung cancer (NSCLC) bringing conflicting findings so far. We performed a systematic review and meta-analysis to synthesize the available evidence regarding to the prognostic value of STAS in NSCLCs.MethodsStudies were identified by searching databases...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Publication date: Available online 25 June 2019Source: Practical Radiation OncologyAuthor(s): Sarah Z. Hazell, Russell K. Hales, William T. Hrinivich, Kristy Ford, Ken Kang-Hsin Wang, Todd R. McNutt, Peijin Han, Lori J. Anderson, Adam C. Ferro, Joseph Moore, Khinh Ranh VoongAbstractPurposeNonhomogeneous dose optimization (NHDO) is exploited in stereotactic body radiation therapy (SBRT) to increase dose delivery to the tumor and allow rapid dose falloff to surrounding normal tissues. We investigate changes in plan quality when NHDO is applied to inverse-planned conventionally fractionated radiation therapy (CF-RT) plans in ...
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsIn our patients with isolated peritoneal metastases from lung cancer, cytoreduction showed good prognosis with acceptable morbidity. This treatment option might be considered in highly selected cases to improve survival. Strict follow-up is mandatory to allow early diagnosis of peritoneal diffusion.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
enkins Lung cancer is the leading cause of cancer-related mortality, which histologically is classified into small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC accounts for approximately 85% of all lung cancer diagnoses, with the majority of patients presenting with lung adenocarcinoma (LAC). KRAS mutations are a major driver of LAC, and are closely related to cigarette smoking, unlike mutations in the epidermal growth factor receptor (EGFR) which arise in never-smokers. Although the past two decades have seen fundamental progress in the treatment and diagnosis of NSCLC, NSCLC still is predomin...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Conditions:   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer Interventions:   Drug: Durvalumab;   Procedure: Surgery;   Radiation: Radiotherapy Sponsors:   Alliance Foundation Trials, LLC.;   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Lung Non-Small Cell Carcinoma;   Stage I Lung Cancer AJCC v8;   Stage IA1 Lung Cancer AJCC v8;   Stage IA2 Lung Cancer AJCC v8;   Stage IA3 Lung Cancer AJCC v8;   Stage IB Lung Cancer AJCC v8;   Stage II Lung Cancer AJCC v8;   Stage IIA Lung Cancer AJC C v8;   Stage IIB Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8 I...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer Interventions:   Drug: Durvalumab;   Procedure: Surgery;   Radiation: Radiotherapy Sponsors:   Alliance Foundation Trials, LLC.;   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biochemistry | Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer